The HCP Engaged. So Why Didn’t Behavior Change?
If an HCP understands the evidence and engages with pharma, why might practice still stay the same? And is another touchpoint really the answer?
The HCP has read the evidence, engaged with the content and had a positive conversation with a field colleague. Yet when the next appropriate patient comes along, practice stays the same. Pharma’s instinct can be to follow up again. But before planning another interaction, shouldn’t we ask a more important question: why?
Of course, no change may be exactly the right outcome. The treatment may not suit that patient, or the HCP may already be making the appropriate decision. Our job is not to manufacture behavior change. It is to understand where an appropriate decision is not happening, what is getting in the way and whether we can help.
Engagement is a signal, not the finish line. An open, a click or a good conversation tells us something happened. It does not tell us whether the HCP has the understanding, confidence or practical ability to act differently. That is what we need to investigate.
Start With the Decision, Then Ask Why
“Improve HCP engagement” is not a behavioral objective. A more useful starting point is the actual decision: test an eligible patient, make a timely referral, initiate appropriate treatment, reassess or continue therapy when clinically justified.
And knowing the decision is only half the job. Why is it not happening? A clinician might accept the value of a test but be unsure exactly when to order it. Another might know when to test but have no workable local pathway. Same apparent lack of progress; very different reasons.
Much of our communications still assumes a “typical patient.” But the patient in the consultation may have comorbidities, an unusual history or a situation the detail aid does not cover. The science can be persuasive in general and still leave the individual decision unresolved.
Diagnose the Barrier, Not Just the Symptom
Three broad gaps can help us make sense of what is happening. An evidence gap means the information does not resolve the real clinical question. A confidence gap means the HCP understands, but does not yet feel ready to act. An execution gap means the intention may be there, but the pathway, access or practical workload gets in the way.
More evidence is not automatically the answer. Sometimes it adds complexity or creates more uncertainty about which finding matters for the patient in front of the HCP. More education can also miss a problem rooted in habit, peer practice, perceived risk or simple inconvenience.
Barriers are rarely uniform. Two specialists with similar prescribing profiles may have quite different attitudes, experiences and local constraints. Attitudinal segmentation, combined with observable behavior and local insight, helps us understand those differences rather than assuming one message will move everyone.
Global Direction Is Not a Local Diagnosis
Global teams play an essential role in establishing the scientific foundation and the decisions a brand should support. But a global communications plan cannot assume that what prevents progress in one market will be the barrier in another.
The evidence may be the same, while referral routes, reimbursement, testing access, institutional habits and treatment pathways differ. Too often, plans and assets are developed before local teams have had enough opportunity to challenge the assumptions behind them.
Global guidance should set direction; affiliates should help diagnose what is actually stopping progress in their markets. Otherwise we risk distributing consistent content that solves inconsistent, or entirely different, problems.
Bring the Field Into the Brief
If we want to know why a decision is not happening, why wouldn’t we speak to the people who regularly hear the HCP’s objections, uncertainties and practical frustrations? Field representatives and medical colleagues can reveal what happens after the evidence has been presented and the conversation has ended.
Yet agencies are not always given direct access to those teams or to local affiliates. There can be legitimate operational and compliance reasons, but it comes at a cost: the people asked to solve the problem may be several steps away from where it actually occurs. Trusting an agency as a partner includes finding appropriate ways to bring those voices into planning.
This does not mean treating every field anecdote as fact. It means asking better questions, looking for recurring patterns and checking those insights against research, data and local experience. The result is a more credible diagnosis and a far stronger brief.
Choose the Intervention Before the Channel
At Syneos Health, our Moments That Matter thinking starts with the points where HCP progress stalls: which decision matters, what may be blocking it and what would help move it forward appropriately.
Sometimes the answer is a clearer scientific explanation or a different conversation. Sometimes it is peer reassurance, patient-identification support, an access solution or a less burdensome process. And sometimes the right intervention is not another piece of communication at all.
This is also what good omnichannel should mean. Not simply coordinating emails, content and field interactions, but coordinating the support around the decision. The channel comes after the intervention, not before it.
Measure Behavior Change, Not Just Engagement
If the aim is more appropriate testing, we should look for evidence of patients being identified and tested, where the data allows. If it is timely referral, we should look at referral behavior. If it is treatment initiation or persistence, we should identify feasible measures closer to those decisions rather than relying only on content performance.
These signals are not always easy to capture, and one communication rarely proves cause and effect on its own. But defining what progress would look like at the start forces us to be clearer about why an activity exists in the first place.
So before asking what pharma should do next, ask: what decision does this HCP need to make, why might it be difficult and what would genuinely help? If we cannot answer those questions, another touchpoint is unlikely to be the place to start.
Let’s find out why HCP behavior is stuck and design the right support to move it forward.
Contributor
Cliff Walton
EU Director, Omnichannel
Syneos Health Communications